The following video is part of our "Motley Fool Conversations" series, in which, Brendan Byrnes, industrials editor/analyst, and David Williamson, health-care editor/analyst, discuss topics across the investing world.
In today's edition, they discuss how Vertex has been beaten down lately as excitement over the next generation of Hep-C treatments has increased concerns that Incivek's blockbuster success will be short-lived. We discuss how the recent planned CEO change will transition the company into more than a one-trick pony. Have a look:
Looking for prediction for 2012? Check out the brand-new report, "The Motley Fool's Top Stock for 2012." It highlights a company that is revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.
At the time thisarticle was published David Williamson and Brendan Byrnes do not own shares of the companies listed above.Motley Fool newsletter serviceshave recommended buying shares of Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.